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Tumbuhan ubatan telah memainkan peranan penting dalam perkembangan budaya 
manusia dan juga dikenali sebagai sumber yang kaya untuk ubat tradisional. Pada masa 
kini, tumbuhan ini digunakan untuk mengasingkan sebatian bioaktif di samping 
menyediakan garis panduan untuk penyelidikan kanser. Kanser adalah antara punca 
utama penyakit dan kematian di seluruh dunia. Penemuan agen antikanser yang berkesan 
dan kesan sampingan yang sedikit amat diperlukan. Usaha telah dilakukan melalui kajian 
ini untuk menilai kesan antikanker ekstrak ubi Dioscorea esculenta (DE) terhadap sel 
kanser payudara, ujian toksik dan pemeriksaan fitokimia. Ekstrak metanol (DEME) dan 
air (DEAE) DE telah disediakan oleh siri pengekstrakan menggunakan teknik makerasi 
dengan eter petrolium dan dietil eter. Sebatian-sebatian fitokimia yang terdapat di dalam 
DE ekstrak telah dinilai dan dikira. Analisis logam berat telah dilakukan melalui ICP-MS 
analisis dan ujian toksik menggunakan ‘brine shrimp lethality assay’. Aktiviti 
antiproliferasi dinilai melalui ujian MTT terhadap sel fibroblast normal (NIH-3T3) dan 
dua sel kanser payudara (MDA-MB-231 dan MCF-7) manakala kesan apoptosis ekstrak 
yang menunjukkan nilai IC50 terendah dengan perencatan berkesan terhadap kanser 
payudara dianalisis oleh Annexin V / FITC PI apoptosis asai. Hasil keputusan 
menunjukkan bahawa DE ekstrak mengandungi banyak kandungan saponin dan ICP-MS 
analisa menunjukkan DE mempunyai kandungan toksik logam berat yang rendah. DE 
ekstrak mempunyai nilai LD50 > 1000 ppm yang dianggap tidak toksik terhadap nauplii 
udang. Sel MDA-MB-231 menunjukkan perencatan yang paling berkesan dengan nilai 
IC50 yang paling terendah apabila dirawat dengan DEME selama 72 jam. Tambahan pula, 
DE ekstrak menunjukkan tidak mempunyai kesan sitotoksisiti terhadap sel normal. 
Analisis flowsitometri telah mengesahkan bahawa MDA-MB-231 sel yang dirawat 
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dengan DEME telah mengakibatkan apoptosis dengan ketara apabila dibandingkan 
dengan kontrol. Oleh itu, DEME menunjukkan aktiviti antiproliferasi dalam MDA-MB-





Medicinal plants have played an essential role in the development of human cultures and 
also known as rich resources for traditional medicines. Nowadays medicinal plants are 
used for isolation of bioactive compounds which also provide a promising line for cancer 
research. Cancer is among the top causes of morbidity and mortality worldwide. 
Discovery of new efficient anticancer agents with reduced side effects are really needed. 
Effort has been made through this study to evaluate anticancer effects of Dioscorea 
esculenta (DE) tuber extract against breast cancer cell lines, toxicity testing and 
phytochemical screening. Methanol (DEME) and aqueous (DEAE) extracts of DE were 
prepared by serial extraction of maceration technique with petroleum ether and diethyl 
ether. Phytochemical compounds present in DE extracts were screened and quantified. 
The toxicity heavy metal analysis was done through ICP-MS analysis while toxicity 
testing by using brine shrimp lethality assay. Antiproliferative activity was evaluated by 
MTT assay against normal fibroblast (NIH-3T3) and two breast cancer (MDA-MB-231 
and MCF-7) cell lines while apoptotic effect of extract that showed the lowest IC50 value 
with effective inhibition of breast cancer was analysed by using Annexin V/FITC PI 
apoptosis assay. The results revealed that DE extracts contained abundance of saponin 
and ICP-MS data showed DE have low concentration of trace toxic heavy metal. The DE 
extracts have LD50 values > 1000 ppm which considered non-toxic against shrimp nauplii. 
MDA-MB-231 cells demonstrated the most effective inhibition with the lowest IC50 value 
upon treatment with DEME for 72 hours. In addition, DE extracts showed no cytotoxicity 
effect towards the normal cells. Flowcytometric analysis has confirmed that MDA-MB-
231 cells treated with DEME was significantly induced apoptosis incomparable with 
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controls. Thus, DEME demonstrated antiproliferative activity in MDA-MB-231 cells by 






1.1 Background of study 
Cancer is the most prominent disease and it causes the most mortality in Malaysia and 
worldwide. Economical changes and transformation in social life contribute to the high 
incidence of cancer cases in most developing countries. Cancer may affect all people 
worldwide either men or women but it is noticed that different type of cancers may give 
a different outcome of incidence rate among the people. According to the World Health 
Organization (WHO), breast cancer is a common cancer among women worldwide and 
in 2018, it was estimated 2.1 million of new breast cancer cases have been diagnosed 
(International Agency for Research on Cancer (IARC), 2018) which accounting for 
almost 1 to 4 breast cancer cases among women (Bray et al., 2018). This uncontrolled 
proliferation of cells which produce cell accumulation within tissues and transform into 
malignant cells have threatened the thousands live of women around the globe.  
 In Malaysia, there are 7, 593 new cases of breast cancer been reported in 2018 
which represents about 17.3% of the total incidence of all type of cancers (IARC, 2018). 
For mortality cases, breast cancer contributed 2, 894 cases (11%) of the total death caused 
by cancer in 2018. However, the actual number of breast cancer incidence in Malaysia 
was difficult to determine because of lack data on cancer registry (Hisham & Yip, 2004). 
Breast cancer incidence showed the highest rate among Chinese as compared to Malay 
and Indian. There are multiple factors associated with the occurrence of breast cancer 
including decrease in childbearing and breastfeeding, increase in exogenous hormone 
receptor as well as dietary and lifestyle changes (Hisham & Yip, 2004). Breast cancer can 
be classified based on distinct histological and molecular features. Early detection of 
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breast cancer such as mammography is very important in order to prevent the 
development of malignant cells from metastasise.  
 Apoptosis is a programmed cell death that is an important mechanism in both 
physiological and pathological conditions. Apoptosis can be triggered by DNA damage, 
signaling imbalance or lack of oxygen supply which the cellular functions cannot be 
maintained and cause cell death. One of the carcinogenesis hallmarks is an evasion of 
apoptosis in which the malignant cells can reduce the apoptosis process and also produce 
apoptosis resistance. Previous studies have demonstrated that more than 50% of neoplasm 
occurred because of the abnormalities in apoptosis (Hotchkiss et al., 2009) and recently, 
many of studies have been conducted to investigate the relationship between apoptosis 
with the development and prevention of cancer (Wong, 2011). Targeting abnormalities 
along the apoptosis pathway are pivotal role in the treatment of carcinogenesis and many 
recent therapeutic strategies have been focusing on this area. These therapeutic strategies 
were applied to restore the normality of apoptotic signaling pathways that give potential 
effect in cancer treatment.  
As for breast cancer, there are many methods been practiced as treatment 
strategies including surgery, radiotherapy, immunotherapy, chemotherapy and 
monoclonal antibodies therapy. Besides high treatment cost and difficulty to access, 
breast cancer therapies always accompanied by the severe side effects like limited 
bioavailability, toxicity, non-specificity, fast clearance and restriction in metastasis 
(Mukherjee & Patra, 2016). Many efforts have been made to minimise the harmful side 
effects of drugs which were used during the process of breast cancer therapy like 
preventing side effects on the neighboring cells and tissues. Until today, even there are 
many efforts have been done, breast cancer still remains as an aggressive killer among 
women around the world. Therefore, the development of new, effective and affordable 
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anticancer drugs become high in demand and most of the researchers are focusing on 
medicinal plants and claimed that these plants have least of side effects (Solowey et al., 
2014).  
Medicinal plants serve as an important part to human which help to pursue a better 
life. Medicinal plants have received high attention over the past 30 years for their potential 
as an anticancer candidate. There are approximately 60% of drugs that been used as 
anticancer currently derived from medicinal plants (Gordaliza, 2007) since plants are the 
most significant source which is easy obtain. Medicinal plants contain many natural 
compounds that have significant value in inhibiting the progression of breast cancer. 
These natural compounds can be isolated from different parts of plants like flower, flower 
stigmas, pericarp, sprouts, fruits, seeds, roots, rhizomes, stem, leaf, tuber, bark (Preeti, 
2013). Several natural compounds including alkaloids, flavonoids, lignans, saponins, 
terpenes, taxanes, vitamins, minerals, glycosides, gums, oils, biomolecules and others 
play a major role in cancer prevention and development.  
In this research, Dioscorea esculenta (Lour.) Burkill (DE) or locally known as 
“ubi itik” has been chosen as a plant of interest. There are claims from old folks with the 
scientific studies showed that this yam species has the potential as an anticancer agent 
(Dina Fatmawati & Sumarno, 2012). This plant contains a high saponin (Senanayake et 
al., 2011) which is a natural compound that has been claimed as a potential anticancer 
(Beit-Yannai et al., 2011; Subramanyam & Immanuel, 2016). Traditionally, this plant has 
also been used as the treatment for several diseases such as beriberi, rheumatism, 
swelling, ulcer, inflammation, fatigue and others (Olayemi & Ajaiyeoba, 2007). DE 
comes in abundant source and it is already been utilised in certain other action as a 
medicinal plant. Since targeting apoptosis is one of strategies in cancer prevention and 
treatment, the potential of DE as anticancer candidate towards breast cancer, 
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phytochemical profile and toxicity properties have been reported throughout this study. 
The findings of this study can provide support to the traditional knowledge of local people 
about using DE in cancer treatment. The mechanism of action of DE towards human 
breast carcinogenesis can be used as a guide for future medicinal practice especially in 
targeting apoptosis for breast cancer treatment.  
 
1.2 Problem statement 
Cancer is the second leading cause of death after heart disease which also 
contributes to global attention in the healthcare system. Breast cancer shows the most 
common cancer that causes high mortality among people worldwide (Bray et al., 2018) 
and requires effective treatment strategies. Plants are reservoirs for novel chemical 
entities and provide a promising line for research on cancer. Nowadays, there are many 
natural plants that thought to be a rich unexplored source of potent anticancer agents 
including yam species. In response to these problems, this study was conducted to 
evaluate anticancer effect of D. esculenta tuber extracts on breast cancer cell line and the 
toxicity testing. 
 
1.3 Objectives  
1.3.1 General objective 
The general objective of this study is to evaluate anticancer effect of D. esculenta tuber 
extracts on breast cancer cell line and the toxicity testing.  
 
1.3.2 Specific objectives  
The specific objectives of this study are: 
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1) To evaluate the phytochemical compounds in DE extracts by using qualitative and 
quantitative analysis. 
2) To investigate the heavy metal content in DE sample using inductively coupled 
plasma mass spectrometry (ICP-MS) and toxicity of DE extracts using brine shrimp 
lethality assay (BSLA). 
3) To evaluate antiproliferative activity of DETE on breast cancer cell lines (MDA-MB-
231 and MCF-7) and normal fibroblast cell line (NIH 3T3). 
4) To investigate the apoptotic effect of DE extract that showed lowest IC50 value on 
breast cancer cell line with the most effective inhibition. 
 
1.4 Hypothesis 
The hypothesis of this study is both methanol and aqueous extract of D. esculenta 
rich with phytochemical compounds that can be used as anticancer agent. This plant 
contains low amount of trace toxic heavy metal and DE extracts not toxic against shrimp 
nauplii. Besides, DE extracts also exhibit anticancer effect against breast cancer cell line. 
 
1.5 Significance of study 
Investigating anticancer properties of DE could have provide guidance and 
support of the traditional usage by local people in using DE for cancer treatment. It also 
provides a wide range of cancer treatment with minimum of side effects. Moving towards 
the natural medicine development, this study could profound scope for discovery of new 








2.1 Cancer  
 For most of the century, the leading incidence and mortality cases in the world is 
heart disease and followed by cancer. Cancer is the most common disease that developed 
among the people worldwide and thus, recently, many of studies related with cancer have 
been conducted by researchers. This disease become global burden to the world since its 
incidence and mortality continues to increase rapidly year by year. 
 
2.1.1 Statistics of cancer 
2.1.1.1 World 
 Based on Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 
database by International Agency for Research on Cancer (IARC), 2018, there are around 
18 million cancer cases around the world in 2018 and from these, 9.5 million cases were 
in men and 8.5 million among women. It has been estimated that the number of cancer 
incidence in the world will increase to more than 11 million by 2040. Global cancer 
incidence shows that lung (11.6%) and breast (11.6%) cancer are the most common 
cancers developed among the people worldwide for both sexes in 2018 (Figure 2.1). 
Colorectal cancer is the third most common cancer with the statistic 1.8 million new cases 
in 2018. In men, lung cancer is the top cancer occurred which contributes 14.5% of the 
total number of new cases diagnosed in 2018 followed by prostate (13.5%) and colorectal 
(10.9%) cancer. It has been reported that breast cancer is the most common cancer among 
women that contributed 24.2% of the total number of new cases diagnosed in 2018. The 
other cancers that occurred in women are colorectal (9.5%), lung (8.4%), cervix uteri 
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Figure 2.1: Estimated number of new cases and death cause by all type of cancers in 
2018 worldwide for both sexes and all ages. Lung cancer is the most common cancer and 





 In Malaysia, there are about 43,837 new cancer incidents (Figure 2.2) and 26,395 
cancer death in 2018. Among the cancer incidences, breast cancer is the most common 
cancer among the people in Malaysia that contributed 17.3% of total number of cancer 
new cases. The second leading cancer in Malaysia for both sexes is colorectal cancer 
(14%) and followed by lung cancer (10.7%). Based on GLOBOCAN database by 
International Agency for Research on Cancer (IARC), 2018, it is estimated that new cases 
of cancer in Malaysia will increase to more than 40 thousand by 2040. Men contributed 
20,000 while women contributed 23,000 of the total number of cancer incidence. The 
report from IARC, 2018 also disclosed that lung cancer was the most commonly 
diagnosed cancer among men followed by colorectal (16.2%) and prostate cancer (8.8%). 
Besides, breast cancer was common cancer occurred among women in Malaysia and it 
contributed 32.7% of the total number of cancer incidence in 2018. The other type of 
cancers that are commonly occurred among women in Malaysia are colorectum (12%), 
cervix uteri (7.2%) and ovary (5.5%). These percentage has been predicted to be arise by 




Figure 2.2: Estimated number of cancer incidence in 2018 among men and women of 
Malaysia population, all ages. Breast cancer is the top leading cancer among the other 




2.1.2 Definition of cancer 
 World Health Organization (WHO) defines cancer as the growth of abnormal cells 
beyond their usual boundaries that can then invade adjoining parts of the body and/or 
spread to other organs (WHO, 2018). Cancer was first named by the Greek physician 
Hippocrates, Father of Medicine that applied the Greek words “carcinoma” and 
“Karakinos” to describe a tumor (Amrish et al., 2018; Sudhakar, 2009). Cancer is the 
second leading disease that cause death after cardiovascular disease (Bray et al., 2018). 
The most common types of cancer among men are lung, prostate, colorectal, stomach and 
liver cancer while in women including breast, colorectal, lung, cervix and thyroid cancer 
(WHO, 2018). According to the National Cancer Institute, when cancer start to grows, 
the cells grow abnormally and can divide without stopping which may form growths 
known as tumour (National Cancer Institute, 2015). Most of the cancerous tumours are 
malignant by which they can spread to nearby tissues and some of them can travel to 
distant part of body through blood vessels and lymph system to form new tumours far 
from the original tumour (National Cancer Institute, 2015).  
 There are also tumours that called benign tumour which this type of tumor does 
not spread or invade to the nearby tissues (National Cancer Institute, 2015). The majority 
causes of cancer are due to environmental factors (Amrish et al., 2018). Environmental 
factors include lifestyle and behavioural exposures. Exposure to chemicals or substances 
in tobacco smoke, radiation and ultraviolet rays can lead to the development of cancer. 
However, cancer also is a genetic disease which can develop due to heredity factor 
(National Cancer Institute, 2015). Cancer can be caused by the changes in genes that play 
important roles in controlling the cell function and growth. These genetic changes can be 
inherited from family or arise from the errors that occur during cell division DNA 
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damage. Mutation in type of genes like proto-oncogenes, tumour suppressor genes and 
DNA repair genes may cause cancer to develop (Amrish et al., 2018).  
 
2.2 Breast cancer 
 Breast cancer is the most common cancer that occurred in women and it is the 
second cancer that newly diagnosed and the cause of death among the other cancers type 
(Bray et al., 2018). There are increasing in number of women that were diagnosed with 
breast cancer in most of the developed countries worldwide. Although breast cancer still 
remains arises in developed countries, breast cancer still continues to emerge as a major 
health problem for women in the world. 
 
2.2.1 Breast cancer statistic 
2.2.1.1 World and Asian Region 
 Worldwide, there are about 2.1 million of breast cancer new cases been diagnosed 
in 2018 (IARC, 2018) and accounting for almost 1 to 4 breast cancer cases among women 
(Bray et al., 2018). Breast cancer is the common type of cancer been diagnosed in the 
majority of developed countries such as United States, China and Australia (154 of 185) 
in the world (Bray et al., 2018). Besides, it is also the top cause of cancer death in over 
100 countries worldwide (Bray et al., 2018). Breast cancer incidence rates in 
Australia/New Zealand, Northern Europe, Western Europe, Netherlands, Southern 
Europe and Northern America show high incidences as compared with the other part of 
the world (Figure 2.3) (IARC, 2018). Age-standardised incidence shows that Australia/ 
New Zealand have the highest rate which is 94.2 per 100,000 (IARC, 2018). According 
to World Health Organization, age-standardisation rate is a weighted average of the age-
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specific rate per 100,000 persons which the weights are the proportions of persons in the 
corresponding age groups of the WHO standard population. 
In higher human development index (HDI) countries, there are elevated breast 
cancer incidences in 2018 which may be contributed by few factors including 
menstruation (early age at menarche, later age at menopause), reproduction (nulliparity, 
late age at first birth, and fewer children), exogenous hormone intake (oral contraceptive 
use and hormone replacement therapy), nutrition (alcohol intake), and anthropometry 
(greater weight, weight gain during adulthood, and body fat distribution) (Bray et al., 
2018). Human development index is an index published by the United Nations 
Development Program which is lists of countries in order of human achievement. This 
index is a summary that measure of average achievement of human development which 
including a long and healthy life, being knowledgeable and have a decent standard of 
living. The purpose of this index is to simulate global, regional and national policy 





Figure 2.3: Region-specific incidence and mortality age-standardised rates for female 
breast cancer worldwide in 2018 (Source: IARC, 2018). 
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Recently, breast cancer incidence is rapidly increasing in Asian populations. In 
India and China, the incidence rate of breast cancer increased over the last 10 years while 
in Japan and Korea, there are doubled or tripled rates of newly cases diagnosed in recently 
as compared with the past few decades (Coughlin & Ekwueme, 2009). Based on 
GLOBOCAN database by the International Agency for Research on Cancer (IARC), 
2018, the age-standardised incidences of breast cancer 2018 which recorded the highest 
rate in Asia region is Korea (310.6 per 100 000) followed by Brunei (232.8 per 100,000), 
Singapore (223.2 per 100,000), Japan (220.5 per 100,000) and China (182.6 per 100,000) 
(IARC, 2018). However, the incidence of breast cancer in Asian women are still lower 
compared with the other Western counterpart across all age groups (Figure 2.4) (IARC, 
2018). In the future, there will be a dramatic increase of breast cancer incidence rates in 
Asian populations due to majority of breast cancer patients worldwide are from the Asian 







Figure 2.4: Estimated age-standardised incidence and mortality based on region-specific 





 Breast cancer is the most common cancer that occurred in women worldwide 
including Malaysia. According to IARC, 2018, there are 7,593 new cases of breast cancer 
reported in 2018 which contributed 17.3% of the total incidence of all type of cancers 
(Figure 2.5) (IARC, 2018). The mortality number of breast cancer is 2,894 cases (11%) 
of the total death 26,395 cases in 2018 (IARC, 2018). The age-standardised rate incidence 
of breast cancer in Malaysia has been estimated to be 47.5 per 100,000 population (IARC, 
2018). However, there is some difficulty in determining the actual number of breast 
cancer incidence in Malaysia because of the lack of cancer registry (Hisham & Yip, 
2004). Based on National Cancer Registry Malaysia, Chinese have the highest incidence 
of breast cancer as compared with Malay and Indian ethnicity. The different rates of breast 
cancer incidence among Chinese, Malay and Indian can be explained by several factors 
including having fewer children, having their first child later, breast-feeding for shorter 
periods and also higher socioeconomic status and diet (Har Yip et al., 2005). Breast 
cancer commonly occurred among younger Malaysian women, aged between 40 to 49 
years as compared to the Western women which the peak prevalence is in the aged of 50 
to 59 years (Hisham & Yip, 2004). Some of Malaysian women having a strong belief in 
traditional medicine to treat the breast cancer compared seeking for available treatment 




Figure 2.5: Estimated number of all type of cancers incidence and mortality among 
Malaysian populations in 2018. Breast cancer is the top leading cancer that been 




2.2.2 Breast cancer 
According to the American Cancer Society, (2017), breast cancer is a disease 
which tumour (cancer) cells form in the breast tissues and the cells start to grow out of 
control (Figure 2.6). The tumor is malignant cells that invade to the surrounding tissues 
or spread (metastasise) to the other parts of body. Breast cancer is the most common 
cancer among women worldwide and it becomes a global burden since it is cause high 
mortality for past few decades until now. Most of the breast cancers begin in the part of 
breast tissue that are made up of gland for milk production (lobules) and ducts which 
connect the lobules to the nipple (ductal) (American Cancer Society, 2017). Historically, 
the physicians like Hippocrates, Galen provide description about abnormal growth in 
breast which refer to breast cancer (Lukong, 2017). Hippocrates believed that 
accumulation of black bile formed in liver during hemostasis that was not eliminated by 
spleen can cause breast cancer (Lukong, 2017) since most of nipple discharge or 




Figure 2.6: Female breast structure. Abnormal cells start to grow out of control and 
accumulation of cells in the breast tissues form a tumour and start to spread to the other 




 Breast cancer usually can be detected during screening examination either the 
symptoms are not developed yet or there is a lump on breast. Based on the World Health 
Organization, early detection is critical which can be categorised into two type, early 
diagnosis and screening. Both diagnosis methods are used to detect the presence of breast 
cancer at the early stage. For example, mammography is uses to detect the masses and 
identify the abnormalities in the breast through low-energy X-rays (WHO, 2018). When 
a patient is diagnosed with breast cancer, the breast tissues is taken by using fine needle 
aspiration or biopsy for further microscopic analysis. When the tumor is small, the breast 
cancer patient usually does not show any symptoms until the tumor becomes big or 
metastasised. 
 
2.2.3 Classification of breast cancer 
 Breast cancer is a heterogeneous disease with histological and biological 
differences. Different types of breast cancer exhibit variable responses toward cancer 
treatment which as the outcome, it will influence breast cancer prognosis ( Viale, 2012; 
Eliyatkin, 2015; Dai et al., 2016). In the past few decades, breast cancer was divided into 
two subtypes based on the status of estrogen receptor (ER) (Dai et al., 2016). The aim of 
breast cancer classification is to aid in the treatment strategies and prognosis (Malhotra 
et al., 2010). There are 20 major types and 18 minor subtypes of breast cancer that have 
been categorised and included in the WHO classification (Eliyatkin, 2015). Generally, 
there are two types of breast cancer classifications which are histopathological and 
molecular classification. The implementation of these classifications make the target 
therapies and especially individualised treatment programs become more possible 




2.2.3.1 Histological classification 
 Histological classification of breast cancer is based on the morphological features 
of the tumour and where the tumour originated either from inner epithelial lining of ducts 
or lobules that supply ducts with milk (Viale, 2012; Makki, 2015). Morphological study 
of breast cancer showed that breast cancer can be limited to the epithelial component (in 
situ carcinoma) or invaded to other parts of tissues and become invasive carcinoma. 
Therefore, breast cancer is broadly divided into two types, in situ carcinoma and invasive 
carcinoma (Figure 2.7). Breast cancer then is sub-classified as either ductal or lobular and 
also its cytological features (Malhotra et al., 2010). Ductal carcinoma in situ (DCIS) are 
epithelial cells have neoplastic proliferation limited to the ducts in which it been 
categorized by potential malignant capacity, cellular and nuclear atypia and non-obligate 





Figure 2.7: Histological classification of breast cancer. Breast cancer are classified based 




DCIS is considered as a precursor lesion for continuous formation of invasive 
breast cancer. Traditionally, DCIS has been divided into few sub-classes which based on 
the architectural hallmarks of tumour and they are comedo, cribiform, micropapillary, 
papillary and solid (Malhotra et al., 2010; Makki, 2015). The grade of DCIS has been 
widely used to determine the severity of DCIS and there are three grades, low-grade DCIS 
(small, micropapillae, cribiform or solid pattern with uniform size of nucleus and regular 
chromatin), intermediate-grade DCIS (cytological similar with low-grade DCIS, duct 
contain intraluminal necrosis and coarse chromatin) and high-grade DCIS (lesion is larger 
than 2 mm, consists of one layer of highly atypical cells, forming micropapillae, cribiform 
or solid pattern with irregular contour and prominent of nucleoli) (Lakhani et al., 2012; 
Makki, 2015). The risk of invasive carcinoma development is proportional to the grade 
of DCIS (Makki, 2015). According to IARC, DCIS is extremely rare to cause death and 
most of death due to undetected invasive component or recurrence of invasive lesion after 
treatment (Lakhani et al., 2012).  
 Lobular carcinoma in situ (LCIS) is small intralobular proliferation and the cells 
are loosely cohesive (Makki, 2015). According to IARC, LCIS can be a risk factor and a 
non-obligatory precursor for the development of invasive carcinoma based on the long 
term follow-up for women with LCIS (Lakhani et al., 2012). LCIS leaves the underlying 
architecture intact which known as lobule and the cells are small to medium size with 
normochromatic nuclei filling the distended lobules (Makki, 2015). The prevalence of 
patients with LCIS is 25% to 35% (about 1% per year) of patients that been observed for 
more than 20 years (Lakhani et al., 2012). The other subtype of breast cancer is invasive 
carcinoma which are tumor heterogeneous groups differentiated into histological 
subtypes. There are seven major subtypes of invasive carcinoma and they are infiltrating 
ductal, invasive lobular, ductal/lobular mucinous (colloid), tubular, medullary and 
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papillary carcinomas (Malhotra et al., 2010). From all these subtypes, infiltrating ductal 
carcinoma (IDC) is the most common subtype among women worldwide which 
contributed 70% to 80% of total breast cancer cases (Malhotra et al., 2010; Eliyatkin, 
2015; Makki, 2015). IDC is breast cancers having malignant ductal proliferation together 
with stroma invasion in the presence or absence of DCIS (Makki, 2015). IDC can be sub-
classified into few groups which are well-differentiated (grade 1), moderately 
differentiated (grade 2) and poorly differentiated (grade 3) where these classifications are 
based on level of nuclear pleomorphism, formation of glandular/tubule and mitotic index 
(Malhotra et al., 2010; Makki, 2015). 
 
2.2.3.2 Molecular classification 
 At the beginning of the new century, many efforts have been concentrated to 
unveil the molecular basis of breast cancer which can provide better prediction of tumor 
behaviour to improve therapeutic strategies. Perou et al., (2000), reported that breast 
cancers can be classified into few distinct subgroups which based on similarities in the 
gene expression profiles by using microarray technology. This new approach has been 
accepted by medical and scientific community and this approach provides new insights 
into biology of breast cancer and give better effect in treatments. There are four defined 
subgroups of breast cancer which are luminal A, luminal B, HER2 overexpression and 
basal like (Perou et al., 2000; Malhotra et al., 2010; Makki, 2015). Luminal A is a breast 
cancer with estrogen receptor (ER) and progesterone receptor (PR) positive and human 
epidermal growth receptor 2 (HER2) negative ( Perou et al., 2000; Eliyatkin, 2015; 
Makki, 2015). The histological features that associated with luminal A breast cancer are 
tubular carcinoma, cribiform  carcinoma, low grade invasive ductal carcinoma and classic 
lobular carcinoma (Eliyatkin, 2015). Luminal A accounts for 50% of the total invasive 
